Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 (Imatinib) and Interferon-alpha in Chronic Phase CML
NCT00015847Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2001
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Complete Cytogenetic Response at 12 months, Minor Cytogenetic Response at 12 months and 4 more. Started Apr 2001; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00015847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015847.